Reason for request
Inclusion on list of products reimbursed by National Insurance and for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of FIRMAGON is substantial. |
Clinical Added Value
| no clinical added value |
In the context of the current strategy for treatment of advanced prostate cancer, with a combination of a Gn-RH analogue and an antiandrogen in the first month of treatment, FIRMAGON provides no improvement in actual benefit (IAB level V). |
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
mw8WvaNmTTneJNjr
